This study shows aging promotes ovarian cancer growth and immunosuppression, which can be mitigated by inhibiting Hedgehog signaling in mice and correlates with immune checkpoint resistance in humans.

bioRxiv · Jul 2, 2026 · PreprintCancer Biology

In vivo genome-wide CRISPR screens in human T cells to enhance T cell therapy for solid tumors

Qi Liu, Peixin Amy Chen, Esha Urs, Shimin Zhang, Maya M. Arce, Charlotte H. Wang, Zhongmei Li, Jin Seo, Nupura Kale, Taylor N. LaFlam, Fanglue Peng, Eric Shifrut, Greg M. Allen, Justin Eyquem, Katherine Cynthia Fuh, , Julia C. Carnevale

This paper performs in vivo CRISPR screens in human T cells to identify genetic modifiers of T cell function in solid tumors, finding P2RY8-G13 and GNAS as key regulators.

bioRxiv · Sep 23, 2025 · PreprintImmunology

Targeting the COP9 signalosome overcomes platinum resistance in ovarian cancer through two distinct genome stability mechanisms

Elena Lomonosova, Megan Loeb, Kevin Rodriguez, Lilian N. van Biljon, Joshua D. Brill, Angela M. Schab, Margaret Minett, Jaeden Barron, Maya Bittner, Jiyoung Park, Rebecca Drexler, Carmen Sandoval, Alyssa Oplt, Eden Gallup, Prasanth Thuthika, , Mary Margaret Mullen

The paper identifies COPS5 as a therapeutic target for overcoming platinum resistance in ovarian cancer by inhibiting nucleotide excision repair and interstrand crosslink repair.

bioRxiv · Aug 4, 2025 · PreprintCancer Biology

Replication stress marker phospho-RPA2 predicts response to platinum and PARP inhibitors in homologous recombination-proficient ovarian cancer

Angela M. Schab, Amanda J. Compadre, Rikki Drexler, Megan Loeb, Kevin Rodriguez, Joshua D. Brill, Shariska Petersen Harrington, Carmen Sandoval, Brooke E. Sanders, Lindsay M. Kuroki, Carolyn Kay McCourt, Andrea R. Hagemann, Premal H. Thaker, David Gardner Mutch, Matthew A. Powell, , Mary Margaret Mullen

This study identifies phospho-RPA2 as a biomarker predicting response to platinum and PARP inhibitors in HR-proficient ovarian cancer, showing higher pathologic complete response and longer survival in pRPA2-High tumors.

Journal of Clinical Investigation · May 20, 2025Peer-reviewedCancer Biology

APOBEC3A drives metastasis of ovarian cancer by altering epithelial-to-mesenchymal transition

Jessica Merritt Devenport, Thi Tran, Brooke R. Harris, Dylan F. Fingerman, Rachel A. DeWeerd, Lojain H Elkhidir, Danielle LaVigne, Katherine Cynthia Fuh, Lulu Sun, Jeffrey J. Bednarski, Ronny Drapkin, Mary Margaret Mullen, Abby M. Green

This study shows APOBEC3A promotes ovarian cancer metastasis by altering epithelial-to-mesenchymal transition in high-grade serous ovarian cancer.

JCI Insight · Mar 9, 2025Peer-reviewedCancer Biology